Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms.

Yang, Joe; Naik, Jaesh; Massello, Matthew; Ralph, Lewis; Dillon, Ryan James

Yang, Joe; Naik, Jaesh; Massello, Matthew; Ralph, Lewis; Dillon, Ryan James.

Afiliação

Yang J; Merck & Co., Inc., Kenilworth, NJ, USA.
Naik J; BresMed Health Solutions Ltd, Sheffield, UK.
Massello M; BresMed Health Solutions Ltd, Sheffield, UK.
Ralph L; BresMed Health Solutions Ltd, Sheffield, UK.
Dillon RJ; Merck & Co., Inc., Kenilworth, NJ, USA. ryan.dillon@merck.com.

Infect Dis Ther ; 11(4): 1443-1457, 2022 Aug.

Article em En | MEDLINE | ID: mdl-35334080

Palavras-chave

Carbapenem non-susceptible; Carbapenem resistance; Colistin; Cost-effectiveness; Economic value; Gram-negative infection; Imipenem/cilastatin/relebactam; QALY

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article